To ask the Secretary of State for Environment, Food and Rural Affairs, whether he has made an assessment of the potential merits of making (a) fipronil and (b) imidacloprid prescription-only.
Answered on
13 May 2025
Parasiticides containing imidacloprid and fipronil play a crucial role in protecting animal and human health against fleas, ticks, and the diseases they spread. The Veterinary Medicines Directorate (VMD) also acknowledges concerns raised about their presence in the environment.
The VMD is gathering evidence on the environmental impact of flea and tick treatments and has led in establishing the cross-government Pharmaceuticals in the Environment (PiE) Group, which has developed a roadmap to help reduce levels of fipronil and imidacloprid in UK surface waters. The immediate priority is to work with stakeholders to promote appropriate use of topical parasiticides for pets, aiming to reduce environmental impacts. Beyond this, actions focus on building our evidence base to inform future policy activities.
While we continue to assess emerging evidence, we consider it essential that these treatments remain appropriately accessible to all pet owners that may need them, in order to effectively manage parasitic disease, which has implications for animal welfare and human health. Therefore, at this stage, there are no plans to restrict flea and tick treatments to prescription. Any future regulatory decisions will be based on robust scientific evidence to ensure both environmental protection and continued access to essential veterinary medicines for pet owners.